10X Genomics IncNASDAQ:TXG
- LAST PRICE16.8700
- TODAY'S CHANGE (%)0.0900 (0.5364%)
- Bid / Lots16.8600/ 1
- Ask / Lots16.8900/ 7
- Open / Previous Close16.4700 / 16.7800
- Day Range
- 52 Week Range
- Volume114,515
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TXG |
|---|---|---|
| 09:32 ET | 14434 | 16.35 |
| 09:33 ET | 4126 | 16.435 |
| 09:35 ET | 1800 | 16.48 |
| 09:37 ET | 2234 | 16.4895 |
| 09:39 ET | 2770 | 16.57 |
| 09:42 ET | 4569 | 16.61 |
| 09:44 ET | 2311 | 16.63 |
| 09:46 ET | 7850 | 16.86 |
| 09:48 ET | 4358 | 16.83 |
| 09:50 ET | 11490 | 16.98 |
| 09:51 ET | 13170 | 17.02 |
| 09:53 ET | 1803 | 16.89 |
| 09:55 ET | 2703 | 16.84 |
| 09:57 ET | 1136 | 16.88 |
| 10:00 ET | 2649 | 16.875 |
| 10:02 ET | 1179 | 16.79 |
| 10:04 ET | 1212 | 16.825 |
| 10:06 ET | 1726 | 16.88 |
| 10:08 ET | 2168 | 16.805 |
| 10:09 ET | 600 | 16.8226 |
| 10:11 ET | 1000 | 16.81 |
| 10:13 ET | 1962 | 16.87 |
Nov 1, 2024
DJ 10x Genomics Is Maintained at Overweight by Barclays, from 9:55AM ET on Friday Nov 01, 2024 by Dow Jones
9:55AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ 10x Genomics Is Maintained at Buy by Citigroup, from 2:43PM ET on Wednesday Oct 30, 2024 by Dow Jones
2:43PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ 10x Genomics Is Maintained at Sell by Goldman Sachs, from 1:10PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:10PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ 10x Genomics Is Maintained at Neutral by JP Morgan, from 12:54PM ET on Wednesday Oct 30, 2024 by Dow Jones
12:54PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
10X Genomics Inc | 2.0B | -11.1x | --- |
Warby Parker Inc | 2.1B | -45.4x | --- |
Tandem Diabetes Care Inc | 2.2B | -16.1x | --- |
UFP Technologies Inc | 2.1B | 51.2x | +24.81% |
Novocure Ltd | 1.8B | -11.9x | --- |
Myriad Genetics Inc | 1.6B | -9.7x | --- |
Company Information
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Contact Information
- Headquarters
- 6230 Stoneridge Mall RoadPLEASANTON, CA, United States 94588
- Phone
- 925-401-7300
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- John Stuelpnagel
- President, Co-Founder, Chief Scientific Officer, Director
- Benjamin Hindson
- Chief Executive Officer, Co-Founder, Director
- Serge Saxonov
- Chief Financial Officer
- Adam Taich
- Chief Commercial Officer
- Mennah Moustafa
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $629.7M |
Shares Outstanding | 121.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-1.53 |
Book Value | $6.22 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -31.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
